'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis

D Bellavia1, P A Pellikka, T P Abraham

  • 1Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

Insights

Cardiac amyloidosis (CA) patients, particularly those with advanced disease, exhibit reduced intraventricular dyssynchrony. Decreased ejection time (ET) is a key factor and a significant predictor of survival in CA patients.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Cardiac Electrophysiology

Background:

  • Mechanical dyssynchrony is observed in various cardiomyopathies.
  • Its presence and significance in cardiac amyloidosis (CA) remain largely uncharacterized.
  • Tissue velocity imaging (TVI) is a tool for assessing cardiac mechanics.

Purpose of the Study:

  • To evaluate mechanical dyssynchrony in patients with primary amyloidosis using TVI.
  • To determine the utility of TVI-derived dyssynchrony parameters for risk stratification in CA.
  • To investigate the relationship between dyssynchrony and survival in CA.

Main Methods:

  • 121 patients with primary amyloidosis and 37 controls were studied.
  • Patients were stratified into advanced-CA and no-advanced-CA groups based on LV wall thickness and diastolic dysfunction.
  • Dyssynchrony was assessed using TVI, including atrioventricular, interventricular, and intraventricular (longitudinal and radial) parameters.

Main Results:

  • Contrary to hypothesis, advanced-CA patients showed reduced intraventricular dyssynchrony (Ts-SD) compared to controls and no-advanced-CA groups.
  • Reduced ejection time (ET) was identified as the primary cause for decreased intraventricular dyssynchrony.
  • ET was the strongest independent predictor of all-cause mortality (HR=0.98, p<0.001).

Conclusions:

  • Patients with advanced cardiac amyloidosis exhibit abnormally synchronized regional systolic motion.
  • Reduced ejection time is a critical factor in the altered mechanics of advanced CA.
  • Ejection time should be considered a vital parameter for assessing survival in cardiac amyloidosis patients.
Abstract